Ndonovo Therapeutics Inc (ENDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2022 | 06-2022 | 03-2022 | 12-2021 | 09-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 23 | N/A | 60 | 86 | 6 |
| Receivables | 1 | 1 | 1 | 1 | 7 |
| TOTAL | $24 | $6 | $64 | $95 | $63 |
| Non-Current Assets | |||||
| Intangibles | 1,427 | 1,589 | 1,751 | 1,912 | 2,074 |
| TOTAL | $1,427 | $1,589 | $1,751 | $1,912 | $2,074 |
| Total Assets | $1,451 | $1,595 | $1,815 | $2,007 | $2,137 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 866 | 786 | 704 | 659 | 753 |
| Accrued Expenses | 3,280 | 3,033 | 2,760 | 2,529 | 2,334 |
| Other current liabilities | 9,592 | 9,500 | 9,015 | 7,334 | 10,416 |
| TOTAL | $20,977 | $20,675 | $19,772 | $17,702 | $20,275 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 80 | 80 | 80 | 80 | 80 |
| TOTAL | $80 | $80 | $80 | $80 | $80 |
| Total Liabilities | $21,057 | $20,755 | $19,852 | $17,782 | $20,355 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 194,327 | 152,478 | 140,628 | 149,528 | 72,014 |
| Common Shares | 16 | 15 | 8 | 7 | 7 |
| Retained earnings | -61,986 | -61,383 | -58,857 | -56,443 | -58,840 |
| Other shareholders' equity | -2 | -1 | -2 | -2 | -2 |
| TOTAL | $-19,606 | $-19,160 | $-18,037 | $-15,774 | $-18,218 |
| Total Liabilities And Equity | $1,451 | $1,595 | $1,815 | $2,007 | $2,137 |